Breo Ellipta, a dual-therapy inhaler combining an ICS and LABA, was similarly found to provide comparable or incremental net health benefits when compared to generic ICS/LABA inhalers.

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...

Recently, the Department of Health and Human Services Office of Inspector General (“OIG”) released Advisory Opinion (“Opinion”) 24-02 regarding patient assistance funds provided by a non ...

GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid ...

Learn about side effects, dosage, cost, and more for Breo Ellipta (fluticasone furoate/vilanterol), a prescription drug that treats COPD and asthma.

Nonprofit Patient Assistance Programs (PAPs), administered by organizations like Access | Accessia Health speaks to changing market conditions and access challenges; demonstrates new approach to ...

Breo Ellipta is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) and asthma. Learn how to find savings and more.

The FDA has expanded the approval of Breo Ellipta to include maintenance treatment of asthma in children 5 to 17 years of age.

Medable offers GSK a decentralized clinical trial platform that includes digital capabilities such as eConsent, TeleVisit, eCOA and the flexibility to deploy modern, patient-centered clinical trials.